Entrada Therapeutics Inc banner

Company Overview

Business Description

Sector
Health Care
Industry
Biotechnology
Headquarters
United States of America US
Employees
152
IPO date
Oct 29, 2021

Entrada Therapeutics is a biotechnology company focused on getting medicines into cells, especially into hard-to-reach tissues like muscle. Its core technology is a delivery platform that helps large drug molecules, such as oligonucleotides and proteins, cross into cells where many diseases actually start. The company is mainly developing these medicines for genetic and neuromuscular diseases, where precise delivery can make a treatment work.

Entrada does not sell a broad portfolio of finished drugs like a traditional pharmaceutical company. Instead, it earns money through research collaboration deals, milestone payments, and future product sales or royalties if its drug candidates are approved and commercialized. Its main customers and partners are other drug companies and, ultimately, patients who would receive the medicines it helps create.

What makes Entrada different is that its business sits at the delivery layer of drug development. Many promising drugs fail because they cannot reach the right cells in the body, and Entrada’s platform is built to solve that problem. That gives the company a role as both a drug developer and a technology partner, with value tied to whether its delivery system can make new classes of medicines practical.

Entrada Therapeutics Inc Investor Relations

Address
One Design Center Place, Suite 17-500
Boston, Massachusetts
United States of America

Business Segments

Drug development

Entrada builds medicines that help large biologic drugs get inside cells, then advances its own treatment candidates through research and clinical testing.

Customers

Patients with serious diseases, through doctors and hospitals that would use an approved Entrada medicine.

Revenue Model

If a drug is approved, Entrada would make money from product sales or licensing payments; until then it mainly spends money developing the candidates.

Partner programs

Entrada also works with pharmaceutical partners to apply its delivery technology to the partners’ drug candidates and discovery programs.

Customers

Drug companies that need help getting their own molecules into cells.

Revenue Model

It earns research payments, collaboration fees, and possible milestone and royalty income from partner agreements.

1 / 2

Management

Mr. Dipal Doshi

CEO & Director

Biography unavailable

Mr. Nathan J. Dowden

President & COO

Biography unavailable

Dr. Natarajan Sethuraman Ph.D.

President of Research & Development

Biography unavailable

Mr. Kory James Wentworth CPA

CFO & Treasurer

Biography unavailable

Dr. Jared Cohen J.D., Ph.D.

General Counsel

Biography unavailable

Ms. Kerry Robert M.S.

Senior Vice President of People

Biography unavailable

Ms. Karla MacDonald

Chief Corporate Affairs Officer

Biography unavailable

Mr. Kevin Healy Ph.D.

Senior Vice President of Regulatory Affairs

Biography unavailable

1 / 8